SP
BravenNow
Crinetics Pharma CFO Schilke sells $266k in stock
| USA | economy | ✓ Verified - investing.com

Crinetics Pharma CFO Schilke sells $266k in stock

#Crinetics Pharmaceuticals #Insider Trading #CFO Stock Sale #Palsonify #Acromegaly Treatment #NASDAQ:CRNX #Q4 2025 Results #Market Outperform

📌 Key Takeaways

  • Crinetics Pharma CFO sold $266k worth of company stock to cover tax obligations
  • The transaction was part of a pre-arranged trading plan involving 6,713 shares
  • Company's Q4 2025 financial results exceeded market expectations
  • Palsonify drug shows strong potential with projected market opportunity of $670M-$1B

📖 Full Retelling

Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke sold $266,304 worth of company stock on March 3, 2026, at an average price of $39.67 per share on the NASDAQ market, to cover tax obligations related to the vesting of restricted stock units granted in 2025. The transaction involved 6,713 shares of Crinetics common stock, with prices ranging between $39.67 and $39.74 per share. Following the sale, Schilke directly owns 78,121 shares of the biopharmaceutical company, and the stock trades at $39.51 as of the transaction date, having declined nearly 10% over the past week, though InvestingPro analysis suggests the $4.14 billion firm appears undervalued at current levels with positive analyst sentiment. This executive stock sale comes amid positive financial performance for Crinetics Pharmaceuticals, as the company reported fourth-quarter 2025 results that exceeded market expectations, achieving an earnings per share of -$1.29 (better than forecasted -$1.34) and reporting revenue of $6.1 million compared to the anticipated $4 million.

🏷️ Themes

Executive Trading, Biopharmaceutical Performance, Market Analysis

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗
Paltusotine

Paltusotine

Chemical compound

Paltusotine, sold under the brand name Palsonify, is a medication used for the treatment of acromegaly. It is a somatostatin receptor 2 agonist. It is taken by mouth.

View Profile → Wikipedia ↗

Crinetics Pharmaceuticals

American pharmaceutical company

Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ i...

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 17 shared
🌐 Restricted stock 4 shared
👤 New York Stock Exchange 3 shared
🌐 EVP 3 shared
🌐 Vice president 3 shared
View full profile

Mentioned Entities

Insider trading

Insider trading

Trading using nonpublic information

 Paltusotine

Paltusotine

Chemical compound

Crinetics Pharmaceuticals

American pharmaceutical company
}
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices jump over 4% as Middle East war escalates, fuels supply fears Iran conflict latest: Hegseth says Iran conflict has "only just begun" Gold hands back gains as US dollar rebounds; Middle East war continues Morgan Stanley explains why gold is falling despite Iran escalation (South Africa Philippines Nigeria) Crinetics Pharma CFO Schilke sells $266k in stock By Insider Trading Published 03/05/2026, 02:33 AM Crinetics Pharma CFO Schilke sells $266k in stock 0 CRNX -1.52% Crinetics Pharmaceuticals NASDAQ:CRNX Chief Financial Officer Tobin Schilke sold 6,713 shares of common stock on March 3, 2026, at an average price of $39.67, for a total transaction value of $266,304. Prices ranged from $39.67 to $39.74.The transaction comes as the stock trades at $39.51, with shares down nearly 10% over the past week. According to InvestingPro analysis, the company appears undervalued at current levels, with the $4.14 billion biotech firm showing positive analyst sentiment. Following the transaction, Schilke directly owns 78,121 shares of Crinetics Pharmaceuticals. The sale was to cover tax obligations related to the vesting of restricted stock units granted on March 10, 2025, and was executed under a pre-arranged Rule 10b5-1 trading plan. In other recent news, Crinetics Pharmaceuticals reported its financial results for the fourth quarter of 2025, exceeding market expectations. The company achieved an actual earnings per share of -$1.29, which was better than the forecasted EPS of -$1.34. Revenue also surpassed estimates, reaching $6.1 million compared to the anticipated $4 million. Additionally, Citizens lowered its price target on Crinetics Pharmaceuticals shares to $96 from $105, while maintaining a Market Outperform rating. This decision was based on early launch metrics for Palsonify, which indicate strong potential for the drug’s adoption in treating acromegaly. Physicians surveyed expect a 20% to 30% adoption ...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine